Medical Condition News

RSS

PAM50 test is now available to classify breast cancer subtypes

ARUP Laboratories, a leading national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, today announced the availability of a new laboratory developed test designed to classify breast cancer into clinically significant molecular subtypes that are important for the management of the disease.

18 Jan 2011

Heart failure patients admitted to general wards fare poorly: Study

The latest research shows that patients with heart failure are twice as likely to die if they are admitted to a general hospital ward rather than one specializing in cardiology. Heart failure kills nearly a quarter of a million people in England and Wales every year and about 900,000 people in the UK have the condition that means the heart is weakened and cannot pump blood efficiently. Symptoms include fatigue, breathlessness and swollen ankles, and it can lead to premature death.

18 Jan 2011

PMT treatment with essential oils: Study

New research has shown that capsules containing a mixture of fatty acids can help relieve symptoms of PMT or Pre-Menstrual Tension - also known as Pre-Menstrual Syndrome (PMS). Women taking the two gram capsules over six months reported their emotional and physical symptoms becoming far milder than they were before.

18 Jan 2011

BSD Medical sells MicroThermX Microwave System to Med-Italia Biomedica

BSD Medical Corporation, a leading provider of medical systems that utilize heat therapy to treat cancer, today announced the sale and shipment of the MicroThermX Microwave System to Med-Italia Biomedica (Med-Italia), one of the largest interventional radiology/oncology distributors in Italy.

18 Jan 2011

Z-Medica develops new version of QuikClot Combat Gauze

Z-Medica Corporation, a medical device company developing innovative hemostatic agents, today announced that it has developed QuikClot Combat Gauze LE, a new version of its QuikClot Combat Gauze dressing specially designed and packaged for use by law enforcement and first responders.

From Medica Corporation 18 Jan 2011

Cardiac surgery market to reach over $4.4 billion by 2017

According to a new report by iData Research, the leading global authority in medical device and pharmaceutical market research, percutaneous aortic valve replacement (PAVR) and percutaneous mitral valve repair (PMVR) devices are expected to enter the U.S. market in 2011 and grow to almost $1.3 billion by 2017.

18 Jan 2011

Transcept announces Intermezzo NDA resubmission for treatment of middle of the night awakenings

Transcept Pharmaceuticals, Inc. today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Intermezzo® for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.

18 Jan 2011

NCI sponsors fourth REOLYSIN clinical trial in pancreatic cancer

Oncolytics Biotech Inc. announced today that the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, U.S. National Cancer Institute (NCI), which is part of the National Institutes of Health, has agreed to sponsor a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN® versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer.

18 Jan 2011

Cadence launches OFIRMEV pain medication in the U.S.

Cadence Pharmaceuticals, Inc. today announced the launch of OFIRMEV™ (acetaminophen) injection, the first and only intravenous (IV) formulation of acetaminophen to be approved in the United States. The U.S. Food and Drug Administration (FDA) approved OFIRMEV in November 2010 for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.

18 Jan 2011

PROLOR and Yeda enter definitive license agreement for Reversible PEGylation technology

PROLOR Biotech, Inc., today announced that it has entered into a definitive license agreement with Yeda Research and Development Company Ltd. for novel technology utilized in the development of long-acting therapeutic peptides and small molecules, termed Reversible PEGylation.

18 Jan 2011

Positive results from Cook Medical's REFORM stent clinical trial for treatment of renal artery stenosis

Study investigators today reported initial data from Cook Medical's REFORM clinical trial that is aimed at assessing the safety and effectiveness of the company's balloon-expandable renal stent for the treatment of renal artery stenosis. The data, presented by Robert Bersin, M.D., at ISET 2011, reveal a nine-month primary patency rate of 89.5 percent and a 97 percent rate of successful delivery and deployment of the stent.

18 Jan 2011

Alexza completes FDA review for AZ-004 NDA

Alexza Pharmaceuticals, Inc. announced today that it completed an End-of-Review meeting with the U.S. Food and Drug Administration (FDA or Agency) for the AZ-004 New Drug Application (NDA), and has received the official FDA minutes from the meeting. In December 2010, Alexza held the End-of-Review meeting in response to a Complete Response Letter (CRL) received in October 2010.

18 Jan 2011

Mylan receives FDA approval for generic Precose Tablets ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Acarbose Tablets, 25 mg, 50 mg and 100 mg, the generic version of Bayer's Precose® Tablets, a treatment to be used with diet and exercise to improve glycemic control in adults with type 2 diabetes.

18 Jan 2011

New study unravels neural mechanisms underlying inability to express emotions

This German study demonstrates that the supragenual anterior cingulate cortex (ACC) is constantly activated more strongly in alexithymic subjects and that this activation is related to the symptoms of alexithymia and not to associated symptoms such as depression. These findings also support the hypothesis of an altered function of the ACC in alexithymia.

18 Jan 2011

Potential device to treat post-operative cognitive decline

It's called post-operative cognitive decline, a syndrome in which patients experience memory loss or other forms of cognitive dysfunction after surgery or critical illness.

18 Jan 2011

Heart failure patients admitted to general wards twice as likely to die

Heart failure patients admitted to general wards are twice as likely to die as those admitted to cardiology wards, shows a national audit of the treatment of the condition, published online in the journal Heart.

18 Jan 2011

Biological Psychiatry publishes special issue focusing on postmortem studies of psychosis

Biological Psychiatry is proud to announce this week's publication of a special issue focusing on postmortem studies of psychosis. This special issue showcases the use of human brains postmortem to study psychiatric disorders, focusing on schizophrenia. The review articles highlight the benefits, achievements, problems, and perhaps most importantly, the future of postmortem research.

18 Jan 2011

Individuals with intensive educational intervention have better health behaviors: Study

A new study conducted by researchers at Columbia University's Mailman School of Public Health examines this issue, using data from a the well-known Carolina Abecedarian Project, a randomized control study that enrolled 111 infants in the 1970s and continued to follow them through age 21. Researchers found that individuals who had received the intensive education intervention starting in infancy had significantly better health and better health behaviors as young adults.

18 Jan 2011

Critical Diagnostics' Presage ST2 Assay effectively risk-stratifies chronic heart failure patients

Critical Diagnostics, the exclusive developer of the Presage® ST2 Assay, announces the publication of the Penn Heart Failure Study (PHFS) in an advance e-publication of the January 19, 2010 edition of Circulation: Heart Failure. The results of this study demonstrated that ST2 levels not only predict outcomes for ambulatory outpatients with chronic heart failure, they more effectively risk-stratify such patients.

18 Jan 2011

Quebec reimburses VIDAZA for treatment of blood cancer

Quebec patients with serious blood cancers (intermediate-2 and high-risk myelodysplastic syndrome and acute myeloid leukemia) now have publicly funded access to a new innovative therapy, VIDAZA® (azacitidine). Following a priority review and subsequent positive recommendation from the Conseil du medicament, patients now have the potential to significantly extend survival.

18 Jan 2011